SpaRx: elucidate single-cell spatial heterogeneity of drug responses for personalized treatment
Open Access
- 22 September 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 24 (6)
Abstract
Spatial cellular authors heterogeneity contributes to differential drug responses in a tumor lesion and potential therapeutic resistance. Recent emerging spatial technologies such as CosMx, MERSCOPE and Xenium delineate the spatial gene expression patterns at the single cell resolution. This provides unprecedented opportunities to identify spatially localized cellular resistance and to optimize the treatment for individual patients. In this work, we present a graph-based domain adaptation model, SpaRx, to reveal the heterogeneity of spatial cellular response to drugs. SpaRx transfers the knowledge from pharmacogenomics profiles to single-cell spatial transcriptomics data, through hybrid learning with dynamic adversarial adaption. Comprehensive benchmarking demonstrates the superior and robust performance of SpaRx at different dropout rates, noise levels and transcriptomics coverage. Further application of SpaRx to the state-of-the-art single-cell spatial transcriptomics data reveals that tumor cells in different locations of a tumor lesion present heterogenous sensitivity or resistance to drugs. Moreover, resistant tumor cells interact with themselves or the surrounding constituents to form an ecosystem for drug resistance. Collectively, SpaRx characterizes the spatial therapeutic variability, unveils the molecular mechanisms underpinning drug resistance and identifies personalized drug targets and effective drug combinations.Keywords
Funding Information
- Comprehensive Cancer Center of Wake Forest University Health Sciences (P30CA012197)
- National Institute of General Medical Sciences
- National Institutes of Health (R35GM151089)
- Indiana University Precision Health Initiative
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center
- National Cancer Institute (P30CA 082709)
- National Library of Medicine of the National Institutes of Health (R01LM013771)
This publication has 43 references indexed in Scilit:
- Microenvironmental regulation of tumor progression and metastasisNature Medicine, 2013
- More than matrix: The multifaceted role of decorin in cancerEuropean Journal of Cell Biology, 2013
- Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cellsNucleic Acids Research, 2012
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- Decorin Antagonizes the Angiogenic NetworkJournal of Biological Chemistry, 2012
- Fibroblast-secreted hepatocyte growth factor plays a functional role in esophageal squamous cell carcinoma invasionProceedings of the National Academy of Sciences, 2010
- Concomitant chemoradiotherapy with cisplatin and docetaxel followed by surgery and consolidation chemotherapy in patients with unresectable locally advanced non-small cell lung cancerMedical Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Osteopontin Combined with CD44, a Novel Prognostic Biomarker for Patients with Hepatocellular Carcinoma Undergoing Curative ResectionThe Oncologist, 2008
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002